Fortrea Holdings (FTRE) Cash from Investing Activities (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Cash from Investing Activities came in at -$7.0 million in Q2 2026, up 6.67% YoY from -$6.6 million in Q2 2025, and up 12.5% on a QoQ basis from -$8.0 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Cash from Investing Activities (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Cash from Investing Activities data on file, last reported at -$7.0 million in Q2 2026.
- Quarterly Cash from Investing Activities rose 6.67% year-over-year to -$7.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$9.2 million (down 330.0% YoY) and the FY2025 annual result came in at $14.4 million, down 94.28% from the prior year.
- Cash from Investing Activities rose to -$7.0 million in Q2 2026, from -$8.0 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $265.4 million in Q2 2024 to a low of -$18.4 million in Q4 2022.
- A 5-year average of $11.5 million and a median of -$7.8 million in 2025 frame the typical range for Cash from Investing Activities.
- The widest YoY moves for Cash from Investing Activities: up 2953.76% in 2024, down 400.0% in 2024.
- Tracing FTRE's Cash from Investing Activities over 5 years: stood at -$18.4 million in 2022, then jumped by 51.09% to -$9.0 million in 2023, then soared by 138.89% to $3.5 million in 2024, then sank by 314.29% to -$7.5 million in 2025, then advanced by 6.67% to -$7.0 million in 2026.
- The last three Cash from Investing Activities figures came in at -$7.0 million (Q2 2026), -$8.0 million (Q1 2026), and -$7.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Fortrea Holdings | 1.72 Bn | 1.55 Bn | 139.20 Mn | -7.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7.00 Mn |
| Mar 31, 2026 | -8.00 Mn |
| Dec 31, 2025 | -7.50 Mn |
| Sep 30, 2025 | 13.30 Mn |
| Jun 30, 2025 | -7.50 Mn |
| Mar 31, 2025 | 16.10 Mn |
| Dec 31, 2024 | 3.50 Mn |
| Sep 30, 2024 | -8.10 Mn |
| Jun 30, 2024 | 265.40 Mn |
| Mar 31, 2024 | -9.20 Mn |
| Dec 31, 2023 | -9.00 Mn |
| Sep 30, 2023 | 2.70 Mn |
| Jun 30, 2023 | -9.30 Mn |
| Mar 31, 2023 | -16.20 Mn |
| Dec 31, 2022 | -18.40 Mn |
| Sep 30, 2022 | -16.90 Mn |